128 related articles for article (PubMed ID: 10622225)
21. Developments in the treatment of acute leukemia in adults.
Volm MD; Tallman MS
Curr Opin Oncol; 1995 Jan; 7(1):28-35. PubMed ID: 7696360
[TBL] [Abstract][Full Text] [Related]
22. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group.
Josting A; Wiedenmann S; Franklin J; May M; Sieber M; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 Sep; 21(18):3440-6. PubMed ID: 12668650
[TBL] [Abstract][Full Text] [Related]
23. The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis.
Griffith TS; Kemp TJ
Cancer Chemother Pharmacol; 2003 Sep; 52(3):175-84. PubMed ID: 12811515
[TBL] [Abstract][Full Text] [Related]
24. Pediatric acute myeloid leukemia: towards high-quality cure of all patients.
Kaspers GJ; Zwaan CM
Haematologica; 2007 Nov; 92(11):1519-32. PubMed ID: 18024401
[TBL] [Abstract][Full Text] [Related]
25. A phase II study of timed sequential therapy of acute myelogenous leukemia (AML) for patients over the age of 60: two cycle timed sequential therapy with topotecan, ara-C and mitoxantrone in adults with poor-risk AML.
Bolaños-Meade J; Guo C; Gojo I; Karp JE
Leuk Res; 2004 Jun; 28(6):571-7. PubMed ID: 15120933
[TBL] [Abstract][Full Text] [Related]
26. Emerging treatments in acute myeloid leukaemia.
Kell J
Expert Opin Emerg Drugs; 2004 May; 9(1):55-71. PubMed ID: 15155136
[TBL] [Abstract][Full Text] [Related]
27. Autologous peripheral blood stem cell transplantation with BCVAC conditioning in childhood acute myeloid leukemia.
Kang HJ; Shin HY; Choi HS; Han KS; Ahn HS
Bone Marrow Transplant; 2004 Mar; 33(5):471-6. PubMed ID: 14716339
[TBL] [Abstract][Full Text] [Related]
28. Progress in the treatment of acute myeloid leukemia.
Ravandi F; Burnett AK; Agura ED; Kantarjian HM
Cancer; 2007 Nov; 110(9):1900-10. PubMed ID: 17786921
[TBL] [Abstract][Full Text] [Related]
29. [Elderly patients with acute myeloid leukemia: characteristics in biology, patients, and treatment].
Wedding U; Bokemeyer C; Meran JG; ; ;
Med Klin (Munich); 2003 Apr; 98(4):193-207. PubMed ID: 12715143
[TBL] [Abstract][Full Text] [Related]
30. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.
Cortes J; Kantarjian H; Albitar M; Thomas D; Faderl S; Koller C; Garcia-Manero G; Giles F; Andreeff M; O'Brien S; Keating M; Estey E
Cancer; 2003 Mar; 97(5):1234-41. PubMed ID: 12599230
[TBL] [Abstract][Full Text] [Related]
31. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children: an evidence-based review.
Oliansky DM; Rizzo JD; Aplan PD; Arceci RJ; Leone L; Ravindranath Y; Sanders JE; Smith FO; Wilmot F; McCarthy PL; Hahn T
Biol Blood Marrow Transplant; 2007 Jan; 13(1):1-25. PubMed ID: 17222748
[TBL] [Abstract][Full Text] [Related]
32. Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients.
Visani G; Lemoli RM; Isidori A; Piccaluga PP; Martinelli G; Malagola M; Gugliotta L; Bonini A; Bonifazi F; Motta MR; Rizzi S; Castellani S; Tura S
Bone Marrow Transplant; 2001 Apr; 27(8):829-35. PubMed ID: 11477440
[TBL] [Abstract][Full Text] [Related]
33. Autologous stem cell transplantation in the treatment of adults with acute myeloid leukaemia.
Breems DA; Löwenberg B
Br J Haematol; 2005 Sep; 130(6):825-33. PubMed ID: 16156852
[TBL] [Abstract][Full Text] [Related]
34. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.
Kantarjian H; Beran M; Cortes J; O'Brien S; Giles F; Pierce S; Shan J; Plunkett W; Keating M; Estey E
Cancer; 2006 Mar; 106(5):1099-109. PubMed ID: 16435387
[TBL] [Abstract][Full Text] [Related]
35. Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I and II resistance: a pharmacodynamically based Phase I trial.
Aisner J; Musanti R; Beers S; Smith S; Locsin S; Rubin EH
Clin Cancer Res; 2003 Jul; 9(7):2504-9. PubMed ID: 12855624
[TBL] [Abstract][Full Text] [Related]
36. The potential role of topotecan in the treatment of advanced breast cancer.
Chang AY
Semin Oncol; 1997 Dec; 24(6 Suppl 20):S20-49-S20-54. PubMed ID: 9425961
[TBL] [Abstract][Full Text] [Related]
37. Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia.
Ferrara F; Palmieri S; Mele G
Haematologica; 2004 Aug; 89(8):998-1008. PubMed ID: 15339685
[TBL] [Abstract][Full Text] [Related]
38. Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission.
Stone RM; DeAngelo DJ; Janosova A; Galinsky I; Canning C; Ritz J; Soiffer RJ
Am J Hematol; 2008 Oct; 83(10):771-7. PubMed ID: 18756547
[TBL] [Abstract][Full Text] [Related]
39. The use of topoisomerase I inhibitors in multiple myeloma.
Kraut EH; Ju R; Muller M
Semin Hematol; 1998 Jul; 35(3 Suppl 4):32-8. PubMed ID: 9779880
[TBL] [Abstract][Full Text] [Related]
40. Amonafide: a future in treatment of resistant and secondary acute myeloid leukemia?
Freeman CL; Swords R; Giles FJ
Expert Rev Hematol; 2012 Feb; 5(1):17-26. PubMed ID: 22272701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
